We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kazia Therapeutics

News List

Kazia Therapeutics to Present at LD Micro Main Event prnasia
October 13, 2021
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event...
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals prnasia
December 09, 2020
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Kazia to use drug with radiotherapy for brain cancer treatment biospectrumasia
July 23, 2019
GDC-0084 is a PI3K inhibitor that can cross the blood-brain barrier, and as such it may be able to reduce the problem of resistance to radiotherapy
Kazia Therapeutics calls for greater awareness of brain cancer in the US biospectrumasia
July 20, 2019
Kazia is developing a drug called GDC-0084 for the treatment of Glioblastoma (GBM) and other cancers, which was licensed from US pharmaceutical group, Genentech and is currently in phase II human trials